Log In Sign up
The largest database of trusted experimental protocols

Rrgfr α1

Manufactured by R&D Systems
Visit Supplier

RrGFR-α1 is a recombinant protein that corresponds to the extracellular domain of the human glial cell line-derived neurotrophic factor receptor alpha 1 (GFRA1). It is a member of the GDNF receptor family that binds to glial cell line-derived neurotrophic factor (GDNF).

Automatically generated - may contain errors

Lab products found in correlation

Stat3, by BD (2 mentions) Rmgfr α2, by R&D Systems (2 mentions) Rrgfr α3, by R&D Systems (2 mentions) Rrgndf, by R&D Systems (2 mentions) Rhnrtn, by Thermo Fisher Scientific (2 mentions) Rhartn, by Thermo Fisher Scientific (2 mentions) P38 mapk erk akt ly294002 ly, by Merck Group (2 mentions) Sb202190, by Merck Group (2 mentions) Pstat3, by Merck Group (2 mentions) P38 mapk, by Cell Signaling Technology (2 mentions) Pd98059, by Merck Group (2 mentions) P38 mapk, by Merck Group (2 mentions)

2 protocols using rrgfr α1

1

Regulation of ILC3 cell signaling pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sorted intestinal ILC3 cells were starved for 3 hours in RPMI at 37°C in order to ensure ILC3 viability. Retfl or RetΔ were analysed directly ex vivo. To test ERK, AKT, p38-MAPK (Cell Signaling Technology) and STAT3 (BD Pharmigen) upon GFL stimulation WT ILC3 were activated with 500ng/mL (each GFL) and co-receptors (rrGFR-α1, rmGFR-α2, rrGFR-α3 and rrGNDF from R&D Systems; rhNRTN and rhARTN from PeproTech) for 10 and 30min. When referring to the use of ‘GFL’, we have employed GDNF, NRTN, ARTN and their specific co-receptors in combination. For inhibition experiments cells were incubated 1h at 37°C before GFL stimulation, to test ERK, AKT, p38/MAPK and STAT3 phosphorylation, or during overnight stimulation with GFLs, to determine Il22 expression levels. Inhibitors were purchased from Sigma-Aldrich: p38 MAPK/ERK-AKT - LY294002 (LY); ERK - PD98059 (PD); AKT - AKT Inhibitor VIII (VIII); p38 MAPK - SB 202190 (SB); and pSTAT3 – S3I-201 (S3I).
Ibiza S., García-Cassani B., Ribeiro H., Carvalho T., Almeida L., Marques R., Misic A.M., Bartow-McKenney C., Larson D.M., Pavan W.J., Eberl G., Grice E.A, & Veiga-Fernandes H. (2016). Glial cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. Nature, 535(7612), 440-443.
+ Open protocol
+ Expand
2

Regulation of ILC3 cell signaling pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sorted intestinal ILC3 cells were starved for 3 hours in RPMI at 37°C in order to ensure ILC3 viability. Retfl or RetΔ were analysed directly ex vivo. To test ERK, AKT, p38-MAPK (Cell Signaling Technology) and STAT3 (BD Pharmigen) upon GFL stimulation WT ILC3 were activated with 500ng/mL (each GFL) and co-receptors (rrGFR-α1, rmGFR-α2, rrGFR-α3 and rrGNDF from R&D Systems; rhNRTN and rhARTN from PeproTech) for 10 and 30min. When referring to the use of ‘GFL’, we have employed GDNF, NRTN, ARTN and their specific co-receptors in combination. For inhibition experiments cells were incubated 1h at 37°C before GFL stimulation, to test ERK, AKT, p38/MAPK and STAT3 phosphorylation, or during overnight stimulation with GFLs, to determine Il22 expression levels. Inhibitors were purchased from Sigma-Aldrich: p38 MAPK/ERK-AKT - LY294002 (LY); ERK - PD98059 (PD); AKT - AKT Inhibitor VIII (VIII); p38 MAPK - SB 202190 (SB); and pSTAT3 – S3I-201 (S3I).
Ibiza S., García-Cassani B., Ribeiro H., Carvalho T., Almeida L., Marques R., Misic A.M., Bartow-McKenney C., Larson D.M., Pavan W.J., Eberl G., Grice E.A, & Veiga-Fernandes H. (2016). Glial cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. Nature, 535(7612), 440-443.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!